Loading…
Loading…
NIB is a framework policy rather than a single statutory instrument: the CNDI (a high-level inter-ministerial council chaired by the President, with seats for industry federations CNI, CUT, sectoral unions and BNDES) sets the missions and targets, and existing agencies operationalise the financing. The architecture is layered:
1. Six missions with 2033 horizon targets. Each mission has a set of quantitative goals — e.g. Mission 1 raises domestic-input share in agro-industrial value chains; Mission 2 rebuilds the "Complexo Econômico-Industrial da Saúde" (CEIS) so that 70% of the SUS public-health system's needs are produced domestically by 2033; Mission 3 commits R$1.6tn in public+private capital to sustainable cities and green mobility; Mission 4 targets Industry 4.0 adoption and a domestic semiconductor footprint (Brasil Semicon, see action 2024-09-11); Mission 5 anchors bioeconomy and the energy transition; Mission 6 (formally goal-set February 2025) covers defence, nuclear, communications and autonomous systems.
2. R$300bn financing envelope through 2026. Disbursed through BNDES (concessional credit lines, often at TR + 2% or TJLP+ spreads), Finep (R&D grants and innovation loans, including the Mais Inovação R$60bn programme — R$40bn credit + R$20bn non-refundable) and Embrapii (industrial-research co-funding). By February 2025, BNDES alone had approved R$220bn in NIB-aligned operations.
3. Local-content and public-procurement preferences. Two presidential decrees signed on the launch day extend Lei 8.666/Lei 14.133 (procurement law) margins of preference for nationally produced goods in New PAC infrastructure bids, particularly for energy transition and urban mobility. An Interministerial Public Procurement Commission was created to define the technical criteria.
4. Sub-programmes that report into NIB missions. Mover (Lei 14.902/2024 — automotive R&D + IPI bonus-malus, filed separately as 2024-06-27-brazil-mover-programme-lei-14902) sits inside Mission 3 / Mission 5. Brasil Semicon (filed as 2024-09-11-brazil-brasil-semicon-program) sits inside Mission 4. Mais Alimentos and the expansion of Brasil Mais Produtivo (SME programme) sit inside Mission 1.
The R$300bn ticket should be read against earlier Brazilian industrial-policy attempts: PSI (Programa de Sustentação do Investimento, 2009-2015) cycled through R$700bn of subsidised BNDES credit at much lower interest spreads, and Plano Brasil Maior (2011-2014) deployed roughly R$25bn in tax breaks. NIB's distinguishing feature is the mission-oriented architecture (borrowed explicitly from Mariana Mazzucato's Mission Economy framework) and the explicit linkage to public-procurement local content.
backdrop for any thesis on Brazilian industrial cyclicals. WEG (capital goods), Embraer (defence + Mission 6), Suzano (Mission 5 bioeconomy) and the BNDES-anchored renewables portfolio all sit inside identifiable NIB mission flows. The R$220bn already approved by BNDES is a non-trivial fraction of Brazilian industrial capex.
target by 2033 is a structural pull for local pharma (Eurofarma, Hypera, Blau Farmacêutica) and the CEIS network of public labs (Bio-Manguinhos/Fiocruz, Butantan, Farmanguinhos). Public buyer is the Sistema Único de Saúde (SUS) — the largest single pharmaceutical buyer in Latin America.
follow-on legislation and ministerial decrees. Mover, Brasil Semicon, Mais Inovação and the procurement preferences are all in flight. Slippage in any one mission risks the credibility of the R$300bn aggregate.
Brazil's tax-reform constitutional amendment (CBS/IBS phasing in from 2026) and against a tightening fiscal framework (Arcabouço Fiscal, Lei Complementar 200/2023). The R$300bn envelope leans heavily on BNDES balance sheet and parafiscal funds (FAT, FNDCT) rather than direct Treasury outlays — by design, to fit inside the spending cap.
largest LATAM industrial-policy package this cycle. Together with Argentina's RIGI (2024) and Mexico's Plan México (2025), it marks a coordinated regional pivot from extraction-only growth toward state-led reindustrialisation, partly catalysed by the Western IRA/CHIPS/CRMA stack.
NIB is partly a defensive-EM response to the post-2022 Western industrial-policy stack: when the US IRA, US CHIPS Act, EU CRMA and EU Chips Act collectively committed >USD 1tn in subsidies to re-anchor manufacturing in consuming countries, EM economies faced an acute capex-flight risk. Brazil's BNDES + Finep re-mobilisation — at a scale unmatched in any LATAM peer — is designed to keep marginal industrial investment from migrating north under FEOC-clean and 45X-credit incentives, while positioning Brazilian agro and bioeconomy supply chains as the EM-aligned alternative input source for Western OEMs.
the Arcabouço Fiscal real-spending growth limit (1.5-2.5% real), or whether parafiscal accounting will need to absorb it.
change. CNDI is statutory but mission targets are administrative.
given Brazilian pharma's ongoing API import dependence on China and India (typical 90%+ for active ingredients).
Seletivo) — local-content preferences and IPI-based incentives embedded in sub-programmes will need re-coding under the new consumption-tax framework.
technology partnership (e.g. with France via the ProSub / Scorpène line, with Sweden via Saab/Gripen) needed to hit the 2033 sovereignty targets.